- Research article
- Open Access
- Open Peer Review
Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing
© Barnett et al.; licensee BioMed Central Ltd. 2014
- Received: 16 December 2013
- Accepted: 25 April 2014
- Published: 7 May 2014
Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its cost-effectiveness.
Using published data describing cognitive decline in the years prior to an AD diagnosis, we modelled the effects on healthcare costs and quality-adjusted life years of hypothetical symptomatic and disease-modifying interventions. Early and standard interventions were assumed to have equal clinical effects, but the early intervention could be applied up to eight years prior to standard diagnosis.
A symptomatic treatment which immediately improved cognition by one MMSE point and reduced in efficacy over three years, would produce a maximum net benefit when applied at the earliest timepoint considered, i.e. eight years prior to standard diagnosis. In this scenario, the net benefit was reduced by around 17% for every year that intervention was delayed. In contrast, for a disease-modifying intervention which halted cognitive decline for one year, economic benefits would peak when treatment effects were applied two years prior to standard diagnosis. In these models, the maximum net benefit of the disease modifying intervention was fifteen times larger than that of the symptomatic treatment.
Timeliness of intervention is likely to have an important impact on the cost-effectiveness of both current and future treatments. Healthcare policy should aim to optimise the timing of AD-dementia diagnosis, which is likely to necessitate detecting and treating patients several years prior to current clinical practice.
- Alzheimer’s disease
- Early intervention
- Health economics
- Cholinesterase inhibitors
Dementia is estimated to affect 36 million people worldwide, costing more than US $600 billion a year . The ageing demographics of both developed and developing nations mean that its prevalence will double over the next 20 years . Alzheimer’s disease dementia (AD-dementia) is the most common form, estimated to account for 60 to 80% of cases . An additional 5-42% of older adults  meet criteria for mild cognitive impairment (MCI), a lesser degree of impairment than dementia, which allows them to continue to function independently .
The current model of Alzheimer’s disease is of a pathological process which starts in mid-life but remains undetected until it causes dementia, at which time a clinical diagnosis of AD-dementia can be made. Recent revisions to diagnostic criteria define three stages of Alzheimer’s disease, namely Alzheimer’s disease dementia , MCI due to AD (MCI-AD) , and preclinical AD . Broadly speaking, the MCI and dementia stages of AD can be determined by a combination of clinical assessment and biomarkers, while detection of preclinical AD, characterised by the absence of overt symptoms, requires brain-related assays of disease progression [9–11]. Within the MCI population a significant proportion have symptoms due to underlying AD pathology (MCI-AD ). Episodic memory impairment is typically a common cognitive marker in those with MCI who progress to AD-dementia, and each year around 15% of individuals with amnestic (memory-impaired) MCI are diagnosed with AD-dementia [5, 9].
Technology now exists that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system ([12, 13]). Timely detection and intervention in AD-dementia can be cost-effective because even though current treatments have limited efficacy, they nonetheless improve symptoms enough to reduce healthcare costs and keep patients living in the community for longer. Although the debate over cost-effectiveness of current treatment is controversial, some economic studies have estimated that timely treatment is cost-effective . A UK study based on 2007 costs estimated that over ten years, timely detection and treatment produced savings of £3600 (US $5508) in direct costs and an additional £4150 ($6350) in indirect costs (caregiver time) per patient . Similar cost-effectiveness has been established for other healthcare systems, including the US . Despite this, in the UK as in other countries, the majority of people with AD-dementia do not have a diagnosis, with up to three quarters undiagnosed in some regions [17–19].
Improved public awareness of AD-dementia is driving older adults who experience memory problems to seek help at an increasingly early stage. At presentation, many of these individuals may meet criteria for MCI-AD for which, as yet, there are no licensed treatments . There is considerable debate within the clinical and public health communities as to the stage at which it is most appropriate to assess and treat people who may have, or be worried about, the early signs of AD-dementia. There is generally little economic evidence about pre-dementia stages of AD (MCI-AD) , but it is likely that resource use increases considerably in the years preceding an AD diagnosis .
One key factor determining when detection and diagnosis programmes should be targeted is understanding at what stage in disease the available interventions are most clinically effective. Unfortunately, there is little data on the size of clinical effect at different stages of disease for even the most common treatments such as cholinesterase inhibitors. It is generally thought that these interventions are more effective when used before widespread pathological change has occurred [23–25], but there is little evidence that they are effective in pre-dementia stages such as MCI-AD [20, 26].
A second major factor is economic: the extent to which healthcare costs and quality of life are changed by intervening at different points in the disease course. In this study we aimed to assess the economic effects of intervening in AD-dementia up to 9 years earlier than that which currently occurs. In the absence of detailed data comparing the efficacy of treatments at different stages, we concentrated only on the economic impact of applying (equally effective) interventions at different points in the disease course. Because few treatments are currently available, we modelled the effects of two hypothetical interventions: one a modestly-effective symptomatic treatment, the other a hypothetical disease-modifying treatment (DMT) that halted cognitive decline for a short period. These two scenarios were chosen as simple and relatively conservative examples of the type of intervention that might plausibly achieve widespread adoption within a healthcare system such as the UK NHS or US Medicare. In this way we aimed to quantify the extent to which the potential costs and savings from an intervention for AD-dementia would be impacted by the time of intervention.
Data and cost assumptions
Our model was based on the reported natural history of cognitive decline in the nine years preceding a diagnosis of Alzheimer’s disease (AD-dementia)  in a longitudinal population-based study in the southwest of France, the Paquid cohort . In this study, cognitive function was monitored in 1285 individuals who were initially assessed as not being demented, including 215 who were subsequently diagnosed with dementia due to Alzheimer’s disease. These data are therefore a description of the average cognitive decline experienced during pre-diagnosis AD. With a mean Mini Mental State Examination (MMSE)  score of around 26 at the start of this time period and 18 at the time of diagnosis, they reflect not the ideal of timely diagnosis but the clinical reality that many patients receive a diagnosis many years after the onset of AD-dementia.
We implemented a cohort model where all individuals follow either the standard pattern of decline or received early intervention as described below. The cost of institutional care, and the relationship between MMSE and direct non-institutional healthcare costs were reported by Knapp & Prince in 2007  based on the UK National Health Service (NHS). These were inflated to 2011 costs using the PSSRU Hospital and Community Health Services Index . Costs and benefits were discounted at a rate of 3.5% per year. The relationship between probability of institutionalisation and MMSE score was derived following Getsios et al’s methodology , based on the national prevalence of AD-dementia severities and the known severity of patients in institutional care .
Our baseline models calculated direct healthcare costs over a ten-year timeframe, including the cost of the diagnostic process where appropriate but excluding indirect costs ascribable to caregiver time. For all scenarios involving an intervention we included the cost of a diagnostic assessment modelled on that recommended by current UK dementia guidelines . This cost a total of £472.94 ($724; 2011 prices based on the Unit Costs of Health and Social Care 2011  and the NHS National Schedule of Reference Costs Years 2011-12 ; see Additional file 1: Table S1) and comprised a GP visit including blood and biochemistry followed by either a CT or MRI scan (50% probability of each), and a memory clinic appointment comprising 60 minutes with a nurse, 45 minutes with a consultant psychiatrist, and with possible additional investigations, namely neuropsychology (10% of patients) and SPECT (5% of patients).
Quality of life scores were combined with survival rates to produce outcomes for quality-adjusted life years (QALYs) which were ascribed a value of £25,000 ($38,250). QALYs were derived based on a modification of a published algorithm  that describes QALYs in terms of MMSE score and independent versus institutional living. The full algorithm is as follows: utility = 0.408 + (0.01 MMSE) - (0.159 if institutionalized) - (0.004 NPI) + (0.051 if living with caregiver). We excluded the two final terms so the utility score was based only on MMSE and institutionalisation. The algorithm was used to ascertain utility for each MMSE score and differences in resulting QALYs in the intervention arm were ascribed based on MMSE score on a monthly basis.
Modelling of interventions
There are various new potential disease-modifying therapies for AD-dementia under research . This model assumed that a hypothetical intervention (based on possible future treatment developments rather than current available interventions), produced no acute change in MMSE but prevented further disease progression (change in MMSE score) for a given period, after which the natural course of decline would resume. This was compared against a model in which no such intervention was applied (‘no intervention’). The baseline case assumed that the intervention produced a 12 month delay in disease progression. Costs and benefits were calculated over a ten year horizon, and a mean age of 75 was assumed at model start. The impact of each of these parameters was then investigated in subsequent analyses.
Maximum economic differences between standard and early interventions, at -8 years, were: diagnostic cost £293 (standard; $448) versus £473 (early; $724); other healthcare costs £97,328 ($112,065) vs £96,608 ($147,810); gain in QALYs 4.246 vs 4.260 (Figure 2). Average diagnostic cost was less for standard intervention because some of those who would receive diagnosis under an early intervention protocol would not survive long enough to receive it under a standard intervention.
Comparison of the effect of timing of intervention for symptomatic versus disease-modifying treatments
The two intervention scenarios had very different effects on the overall course of cognitive function. For the symptomatic treatment, the benefits of intervention were inherently time-limited and roughly equal in magnitude with respect to the overall effect on cognitive course (area under the curve in Figure 1A). In contrast, the nature of the disease-modifying intervention was such that the immediate effect of the intervention was driven by the nature of the cognitive decline function at the time of intervention, and the majority of the effect on cognition was seen relatively late in the decline curve (Figure 1B). In absolute terms, the maximum net benefit of the disease modifying intervention modelled here was fifteen times greater than for the modelled symptomatic treatment.
In this study we utilised the known natural history of cognitive decline in Alzheimer’s disease to estimate the health economic impact of earlier intervention. We modelled two hypothetical scenarios; one a symptomatic drug with effects similar to those seen for cholinesterase inhibitors, the other a disease-modifying intervention that delayed cognitive deterioration for a period of time. In both cases, results showed that optimally timing an intervention could significantly affect its economic benefits. For the symptomatic treatment, the economic benefits were greater the earlier the intervention was applied; in contrast the disease-modifying intervention was most cost-effective when applied relatively late in the course.
These differences in optimal timing between symptomatic and disease-modifying models can be explained by the effects of mortality on post-diagnostic healthcare costs and by the changing rate of cognitive decline throughout the disease course. For the symptomatic intervention, treatment benefits are immediate and decrease over a fixed time period. Intervention is consequently most effective when applied at the earliest possible timeframe, so that the greatest number of individuals benefit from the intervention before any loss to mortality. However the effect of this intervention is relatively small because it is inherently time-limited. In contrast, in the disease-modifying model, while there is no immediate impact, the effect of intervention is to permanently shift the curve of cognitive decline. As a result, the effect on both healthcare costs and QALYs is considerably larger. Under this scenario, intervention was most economically beneficial when applied around two years prior to the time of standard diagnosis. This is the period during which MMSE decline is most rapid: intervening either earlier or later than this reduces the costs saved by delaying cognitive decline.
Other health economic models of disease modifying treatments have also estimated higher costs with DMT over time, due to additional costs of DMT and the increased survival with DMT .
Of the two interventions, the results from the symptomatic model are more immediately applicable because moderately effective symptomatic treatments are already available in the UK for patients with mild to severe AD -dementia (MMSE of 26 or below). In this cohort, individuals already had a mean MMSE score indicating AD-dementia treatment up-to nine years before diagnosis, so these results are in one sense supporting not ‘early’, but rather ‘on time’ intervention. While we have not included treatment costs in the model, generic AD-dementia drugs now cost just pennies per day. These results therefore support previous analyses demonstrating the cost-effectiveness of intervention and treatment using symptomatic treatments in the NHS, and extend this by arguing that intervention will be more cost-effective when applied earlier than currently occurs for the majority of patients.
The disease-modifying results should not be interpreted to mean that we can wait until frank dementia before intervening. On the contrary, to maximise the cost-effectiveness of a disease-modifying strategy, the benefits of such a treatment must be being felt before patients hit the period of rapid decline that precedes a diagnosis in this cohort. In order to prevent this precipitous decline it will, at a minimum, be necessary to detect and closely monitor individuals with milder cognitive impairment so that intervention can be certain to occur prior to that point of inflection. In all likelihood, the mode of action of such an intervention, be it a lifestyle prevention strategy or anti-amyloid immunisation, would probably need intervention to start many years or decades earlier in order to have an impact on cognitive course.
Our model included full direct health and social care costs and the cost of the diagnostic procedure but excluded any costs associated with informal caregiver time [39, 40], and, importantly, the cost of the intervention itself. This might range from a few pounds per month for a generic drug such as a cholinesterase inhibitor to many thousands for a future biological therapy. Alternatively, modification of disease course and its impact, could potentially be obtained from non-pharmacological strategies such as lifestyle intervention which might be required decades earlier (i.e. as a primary prevention strategy) in order to prevent the disease process from occurring . Although excluding the cost of informal care narrows the viewpoint somewhat, excluding these costs takes a conservative approach. Including caregiver costs would cause the results to be more favourable towards early detection. A sensitivity analysis demonstrated that the inclusion of a cost associated with the intervention has a linear impact on the model’s findings. That is, if the cost of the intervention is £50, then the total cost savings associated with early detection will be reduced by £50. If the cost of the intervention is £200, the cost savings are reduced by £200.
We did not include in our models a specific cost of treatment, so these results provide a framework for estimating the likely bearable costs to the UK health system for a sufficiently effective anti-dementia intervention. The results show that cost-effectiveness might be achieved with either a cheap symptomatic treatment or a more expensive disease-modifying one. The treatment effects modelled here were purposefully modest and reflect the relatively small effects achieved thus far in both approved and developing compounds. While both the healthcare costs and QALY values used here are taken from the UK system, the principles are likely to apply widely within European and North American countries, where under-diagnosis is common [17–19] and where any intervention which improved the function of AD-dementia patients would be expected to have a proportionally similar effect on healthcare costs .
An important limitation of the model is the assumption that the efficacy of the intervention does not depend on when it is applied, either with respect to illness severity, or to cohort age. At present little data exists addressing this for existing treatments, although for future anti-amyloid therapies intervention is likely to be more effective when applied earlier in disease course. Age at treatment start is particularly important because at the older ages, mortality plays an increasing role in exaggerating the economic differences between early and standard intervention. In the absence of published data, we ignored the effect of treatment on survival, whilst in reality disease-modifying interventions, in particular, would be expected to play a role in reducing mortality. All of these limitations are conservative in nature and would lead, if anything, to an underestimation by the present model of the benefits of earlier intervention.
The model also does not take into account the possible effect of false positives. As diagnoses of AD-dementia shifts to earlier disease states the difference between pathological symptoms and normal age-related cognitive decline is likely to be subtle, with the potential for greater diagnostic uncertainty, leading to an increased risk of a false positive diagnosis (Albert, 2011). Due to a lack of data this was not included in the model; however the likely impact of including this would be that in earlier diagnosis there are more false positives, leading to treatment costs increasing, while no extra benefit is incurred. This should be considered in future studies and when translating our analyses.
In summary, we demonstrate that for both symptomatic and disease-modifying interventions, timing is crucial in determining the economic benefits of a treatment, even leaving aside the issue of treatment efficacy. Early intervention is clearly indicated for current symptomatic treatments, which are likely to be most cost-effective when applied as early as it is possible to diagnose AD-dementia. For a disease-modifying intervention, maximal cost-effectiveness would be achieved by intervening early enough to anticipate the point at which cognition begins a rapid decline. Taken together, these results suggest that cost-effective early detection and intervention should be an achievable goal in earlier stages of AD (MCI-AD), and that a range of different intervention effects and costs might be manageable or even beneficial in terms of overall healthcare costs. Public policy including screening, diagnostic and prescribing guidelines should aim to reflect the optimal cognitive stage for cost-effective intervention, which will be several years prior to current standard practice.
We would like to thank Dr Rebecca Rous, Dr Charlotte R Housden and Alexandra Filby for their contribution to final drafting and responding to the reviewer’s comments in this manuscript.
Cambridge Cognition is involved in a series of health economic studies related to dementia. This study was funded independently by Cambridge Cognition and was not supported by grant funding.
- Wimo A, Prince M: World Alzheimer Report 2010: The Global Economic Impact of Dementia. 2010, UK, London: Alzheimer’s Disease InternationalGoogle Scholar
- Prince M, Jackson J: World Alzheimer Report 2009. 2009, UK, London: Alzheimer’s Disease InternationalGoogle Scholar
- Alzheimers Association: 2011 Alzheimer’s disease facts and figures. Alzheimers Dement. 2011, 7: 208-244.View ArticleGoogle Scholar
- Ward A, Arrighi HM, Michels S, Cedarbaum JM: Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. 2012, 8: 14-21. 10.1016/j.jalz.2011.01.002.View ArticlePubMedGoogle Scholar
- Petersen RC: Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch Neurol. 1999, 56: 303-308. 10.1001/archneur.56.3.303.View ArticlePubMedGoogle Scholar
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 263-269. 10.1016/j.jalz.2011.03.005.View ArticlePubMedPubMed CentralGoogle Scholar
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 270-279. 10.1016/j.jalz.2011.03.008.View ArticlePubMedPubMed CentralGoogle Scholar
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7: 280-292. 10.1016/j.jalz.2011.03.003.View ArticlePubMedPubMed CentralGoogle Scholar
- Blennow K, Hampel H: CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003, 2: 605-613. 10.1016/S1474-4422(03)00530-1.View ArticlePubMedGoogle Scholar
- Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K: Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010, 9: 560-574. 10.1038/nrd3115.View ArticlePubMedGoogle Scholar
- Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB: Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 2010, 31: 1443-1451. 10.1016/j.neurobiolaging.2010.04.036. 1451.e1View ArticlePubMedGoogle Scholar
- Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004, 17: 42-48. 10.1159/000074081.View ArticlePubMedGoogle Scholar
- The Brain Health Centre, powered by Ixico and Cambridge Cognition Ltd. http://www.thebrainhealthcentre.com/,
- Geldmacher DS: Cost-effectiveness of drug therapies for Alzheimer’s disease: A brief review. Neuropsychiatr Dis Treat. 2008, 4: 549-555.PubMedPubMed CentralGoogle Scholar
- Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L: An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 2012, 8: 22-30. 10.1016/j.jalz.2010.07.001.View ArticlePubMedGoogle Scholar
- Weimer DL, Sager MA: Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimers Dement. 2009, 5: 215-226. 10.1016/j.jalz.2009.01.028.View ArticlePubMedPubMed CentralGoogle Scholar
- Alzheimer's Society: Mapping the Dementia Gap. 2012, UK, London: Alzheimer’s SocietyGoogle Scholar
- Bradford A, Kunik ME, Schulz P, Williams SP, Singh H: Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009, 23: 306-314. 10.1097/WAD.0b013e3181a6bebc.View ArticlePubMedPubMed CentralGoogle Scholar
- Song Y, Skinner J, Bynum J, Sutherland J, Wennberg JE, Fisher ES: Regional variations in diagnostic practices. N Engl J Med. 2010, 363: 45-53. 10.1056/NEJMsa0910881.View ArticlePubMedPubMed CentralGoogle Scholar
- Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE: Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013, 185: 1393-1401. 10.1503/cmaj.130451.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin P-J, Neumann PJ: The economics of mild cognitive impairment. Alzheimers Dement. 2013, 9: 58-62. 10.1016/j.jalz.2012.05.2117.View ArticlePubMedGoogle Scholar
- Albert SM, Glied S, Andrews H, Stern Y, Mayeux R: Primary care expenditures before the onset of Alzheimer’s disease. Neurology. 2002, 59: 573-578. 10.1212/WNL.59.4.573.View ArticlePubMedGoogle Scholar
- Cummings JL, Doody R, Clark C: Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007, 69: 1622-1634. 10.1212/01.wnl.0000295996.54210.69.View ArticlePubMedGoogle Scholar
- Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L: Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008, 179: 787-793. 10.1503/cmaj.070803.View ArticlePubMedPubMed CentralGoogle Scholar
- Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001, 56: 1154-1166. 10.1212/WNL.56.9.1154.View ArticlePubMedGoogle Scholar
- Cooper C, Li R, Lyketsos C, Livingston G: Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013, 203: 255-264. 10.1192/bjp.bp.113.127811.View ArticlePubMedPubMed CentralGoogle Scholar
- Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues J-F: The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005, 128 (Pt 5): 1093-1101.View ArticlePubMedGoogle Scholar
- Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C, Michel P, Salamon R: The Paquid epidemiological program on brain ageing. Neuroepidemiology. 1992, 11 (Suppl 1): 14-18.View ArticlePubMedGoogle Scholar
- Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.View ArticlePubMedGoogle Scholar
- Knapp M, Prince M: Dementia UK: A Report to the Alzheimer’s Society on the Prevalence and Economic Cost of of Dementia in the UK. 2007, London: Alzheimer's SocietyGoogle Scholar
- Curtis L: Unit Costs of Health and Social Care 2011. 2011, UK: CanterburyGoogle Scholar
- Macdonald A, Cooper B: Long-term care and dementia services: an impending crisis. Age Ageing. 2007, 36: 16-22.View ArticlePubMedGoogle Scholar
- National Collaborating Centre for Mental Health: Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. 2007, UK, London: The British Psychological SocietyGoogle Scholar
- Department of Health: NHS Reference Costs: Financial Year 2011 to 2012. 2012, UK, London: Department of HealthGoogle Scholar
- Jönsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jönhagen ME, Hallikainen M, Wimo A: Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006, 20: 49-55. 10.1097/01.wad.0000201851.52707.c9.View ArticlePubMedGoogle Scholar
- Office of National Statistics: Interim Life Tables, 2008–2010. 2011, http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2008-2010/index.html,Google Scholar
- Yiannopoulou KG, Papageorgiou SG: Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013, 6: 19-33. 10.1177/1756285612461679.View ArticlePubMedPubMed CentralGoogle Scholar
- Sköldunger A, Johnell K, Winblad B, Wimo A: Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease–a simulation study. Curr Alzheimer Res. 2013, 10: 207-216. 10.2174/1567205011310020011.View ArticlePubMedGoogle Scholar
- Gervès C, Chauvin P, Bellanger MM: Evaluation of full costs of care for patients with Alzheimer’s disease in France: The predominant role of informal care. Health Policy. 2014, 116: 114-122. 10.1016/j.healthpol.2014.01.001.View ArticlePubMedGoogle Scholar
- Gillespie P, O’Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A: The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry. 2013, 28: 256-264. 10.1002/gps.3819.View ArticlePubMedGoogle Scholar
- Schneider N, Yvon C: A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging. 2013, 17: 252-257. 10.1007/s12603-012-0402-8.View ArticlePubMedGoogle Scholar
- Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L: Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011, 7: 318-327. 10.1016/j.jalz.2010.09.001.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2377/14/101/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.